The Comparative Effectiveness of Botulinum Toxin-A Injection Therapy Versus Augmentation Uretero-Enterocystoplasty for the Treatment of Lower Urinary Tract Dysfunction
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
urpose: We investigated the effectiveness of intravesical botulinum toxin-A (BTX-A) injection therapy in patients with lower urinary tract dysfunction (LUTD) and upper urinary tract (UUT) deterioration and evaluated whether BTX-A injection therapy could substitute for augmentation uretero-enterocystoplasty (AUEC). Methods: Data from a prospective, single-center cohort from 2017–2021 were analyzed. Patients were divided into 2 treatment groups: AUEC and BTX-A (i.e., patients who declined AUEC). Bladder and UUT functions were assessed by comparing clinical information, urodynamic data, laboratory results, and imaging records. Results: In total, 121 patients were enrolled (BTX-A group: 41 patients; AUEC group: 80 patients). The BTX-A group showed a reduced maximum detrusor pressure and increases in the maximum bladder volume and bladder compliance (P<0.05). However, in follow-up evaluations, significantly smaller improvements (all P<0.05) in urodynamic parameters were found in the BTX-A group than in the AUEC group. Notably, there was no significant improvement in vesicoureteral reflux (VUR; P=0.66) or upper urinary tract dilatation (UUTD; P=0.75) in the BTX-A group, and no statistically significant difference in serum creatinine (Scr) levels or the estimated glomerular filtration rate (eGFR) was observed in the follow-up evaluations (all P>0.05). Both VUR and UUTD improved significantly in the AUEC group, and the Scr and eGFR levels significantly improved after AUEC relative to baseline levels (P<0.05). The reduction in the Scr level was significantly lower in the BTX-A group than in the AUEC group during 0–15 months of follow-up (Scr reduction differences, -1.36; P<0.01). Conclusions: Although BTX-A injection therapy was effective for improving bladder function, BTX-A injections did not alleviate UUT deterioration in this study, particularly in patients with advanced-stage LUTD. Conversely, AUEC for LUTD has a well-established role in improving UUT function. Hence, BTX-A injection therapy should not replace AUEC to ameliorate UUT impairment and protect UUT function.
Abstract
urpose: We investigated the effectiveness of intravesical botulinum toxin-A (BTX-A) injection therapy in patients with lower urinary tract dysfunction (LUTD) and upper urinary tract (UUT) deterioration and evaluated whether BTX-A injection therapy could substitute for augmentation uretero-enterocystoplasty (AUEC). Methods: Data from a prospective, single-center cohort from 2017–2021 were analyzed. Patients were divided into 2 treatment groups: AUEC and BTX-A (i.e., patients who declined AUEC). Bladder and UUT functions were assessed by comparing clinical information, urodynamic data, laboratory results, and imaging records. Results: In total, 121 patients were enrolled (BTX-A group: 41 patients; AUEC group: 80 patients). The BTX-A group showed a reduced maximum detrusor pressure and increases in the maximum bladder volume and bladder compliance (P<0.05). However, in follow-up evaluations, significantly smaller improvements (all P<0.05) in urodynamic parameters were found in the BTX-A group than in the AUEC group. Notably, there was no significant improvement in vesicoureteral reflux (VUR; P=0.66) or upper urinary tract dilatation (UUTD; P=0.75) in the BTX-A group, and no statistically significant difference in serum creatinine (Scr) levels or the estimated glomerular filtration rate (eGFR) was observed in the follow-up evaluations (all P>0.05). Both VUR and UUTD improved significantly in the AUEC group, and the Scr and eGFR levels significantly improved after AUEC relative to baseline levels (P<0.05). The reduction in the Scr level was significantly lower in the BTX-A group than in the AUEC group during 0–15 months of follow-up (Scr reduction differences, -1.36; P<0.01). Conclusions: Although BTX-A injection therapy was effective for improving bladder function, BTX-A injections did not alleviate UUT deterioration in this study, particularly in patients with advanced-stage LUTD. Conversely, AUEC for LUTD has a well-established role in improving UUT function. Hence, BTX-A injection therapy should not replace AUEC to ameliorate UUT impairment and protect UUT function.
참고문헌 (26)
- Ginsberg DA, "The AUA", SUFU guideline on adult neurogenic lower urinary tract dysfunction : diagnosis and evaluation, 2021, pp.206, 1097~1105
- Yuan-Hong Jiang, "Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction", International Neurourology Journal, 24(4), pp.301~312 (2020), 대한배뇨장애요실금학회[DOI]
- Ying X, "Augmentation uretero-enterocystoplasty for refractory urinary tract dysfunction : a long-term retrospective study", BMC Urol, 21, pp.166~ (2021)
- Wang X, "Current applications and future directions of bioengineering approaches for bladder augmentation and reconstruction", Front Surg, 8, pp.664404~ (2021)
- Liao L, "Hengli((R)) Chinese botulinum toxin type A for treatment of patients with overactive bladder: a multicenter, prospective, randomized, double-blind, placebo-controlled trial", Front Pharmacol, 13, pp.840695~ (2022)
- Michel F, "Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity:preliminary results of a salvage strategy. The ENTEROTOX Study", Urology, 129, pp.43~47 (2019)
- Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
- Zhang F, "Sigmoidocolocystoplasty with ureteral reimplantation for treatment of neurogenic bladder", Urology, 80, pp.440~445 (2012)
- Wang Z, "Effectiveness and complications of augmentation cystoplasty with or without nonrefluxing ureteral reimplantation in patients with bladder dysfunction : a single center 11-year experience", J Urol, 199, pp.200~205 (2018)
- Liao L, "Midterm outcomes of protection for upper urinary tract function by augmentation enterocystoplasty in patients with neurogenic bladder", Int Urol Nephrol, 46, pp.2117~2125 (2014)
- Liao L, "A new comprehensive classification system for both lower and upper urinary tract dysfunction in patients with neurogenic bladder", Urol Int, 94, pp.244~248 (2015)
- Liao L, "New grading system for upper urinary tract dilation using magnetic resonance urography in patients with neurogenic bladder", BMC Urol, 14, pp.38~ (2014)
- Martinez L, "Refractory bladder dysfunction : a multi-institutional experience with intravesical botulinum toxin-a injection in adult patients who underwent previous augmentation cystoplasty", Turk J Urol, 46, pp.309~313 (2020)
- Gurung PM, "Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury : a minimum of 10 years of follow-up", BJU Int, 109, pp.1236~1242 (2012)
- Shreck E, "Indications for augmentation cystoplasty in the era of onabotulinumtoxinA", Curr Urol Rep, 17, pp.27~ (2016)
- Gao Y, "Intravesical injection of botulinum toxin A for treatment of interstitial cystitis", bladder pain syndrome : 10 years of experience at a single center in China, 2015, pp.26, 1021~1026
- Lin CC, "Video-urodynamic characteristics and predictors of switching from botulinum neurotoxin a injection to augmentation enterocystoplasty in spinal cord injury patients", Toxins(Basel), 14, pp.47~ (2022)
- Hoebeke P, "The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor", J Urol, 176, pp.328~331 (2006)
- Schulte-Baukloh H, "Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder", Eur Urol, 44, pp.139~143 (2003)
- Chen G, "Injections of botulinum toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury", Int Urol Nephrol, 43, pp.655~662 (2011)
- Reitz A, "European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity", Eur Urol, 45, pp.510~515 (2004)
- Hassouna T, "Botulinum toxin A’s expanding role in the management of pediatric lower urinary tract dysfunction", Curr Urol Rep, 15, pp.426~ (2014)
- Kajbafzadeh AM, "Intravesical electromotive botulinum toxin type A administration--part II : clinical application", Urology, 77, pp.439~445 (2011)
- Marte A, "Onabotulinumtoxin A for treating overactive", poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele, 2012, pp.5, 16~24
- Padmanabhan P, "Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity", World J Urol, 29, pp.51~57 (2010)
- Anquetil C, "Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty : impact on the quality of life of patients with SCI", Spinal Cord, 54, pp.1031~1035 (2016)